奥司他韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "奥司他韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

39web.archive.org

1^st place

38doi.org

2^nd place

23^rd place

36nih.gov

4^th place

5^th place

9semanticscholar.org

11^th place

332^nd place

6fda.gov

447^th place

581^st place

5cdc.gov

218^th place

198^th place

4harvard.edu

18^th place

57^th place

2drugs.com

399^th place

208^th place

2tga.gov.au

3,984^th place

1,603^rd place

2europa.eu

68^th place

209^th place

2theatlantic.com

228^th place

597^th place

2handle.net

102^nd place

492^nd place

2bmj.com

1,226^th place

890^th place

2clincalc.com

3,912^th place

5,917^th place

2who.int

195^th place

179^th place

1guildlink.com.au

low place

1nice.org.uk

3,258^th place

2,433^rd place

1idsociety.org

low place

6,969^th place

1archive.org

6^th place

4^th place

1gov.uk

432^nd place

770^th place

1reuters.com

49^th place

81^st place

1rocheusa.com

low place

1medscape.com

719^th place

889^th place

1nc.gov

low place

1wipo.int

1,462^nd place

2,636^th place

1umn.edu

1,266^th place

1,781^st place

1uq.edu.au

3,558^th place

2,972^nd place

1indiatimes.com

17^th place

397^th place

1sina.com.cn

144^th place

3^rd place

1vin.com

low place

archive.org (Global: 6^th place; Chinese: 4^th place)

World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. 2017. ISBN 9789241210157. hdl:10665/259481 . WHO technical report series;1006. License: CC BY-NC-SA 3.0 IGO.

bmj.com (Global: 1,226^th place; Chinese: 890^th place)

Ebell MH. WHO downgrades status of oseltamivir. BMJ. July 2017, 358: j3266 [2020-08-31]. PMID 28701339. S2CID 206916214. doi:10.1136/bmj.j3266. （原始内容存档于2023-04-29）.
Tamiflu campaign. BMJ. [2020-01-21]. （原始内容存档于2020-01-21）.

cdc.gov (Global: 218^th place; Chinese: 198^th place)

CDC Recommendations for Influenza Antiviral Medications Remain Unchanged. U.S. Centers for Disease Control and Prevention (CDC). 2014-04-10 [2017-01-16]. （原始内容存档于2017-01-18）.
Influenza Antiviral Medications: Summary for Clinicians. U.S. Centers for Disease Control and Prevention (CDC). 2014-12-03 [2014-12-09]. （原始内容存档于2014-12-13）.
2010-2011 Influenza Season Summary. U.S. Centers for Disease Control and Prevention (CDC). （原始内容存档于2012-01-25）.
2011-2012 Influenza Season Week 51 ending December 24, 2011. U.S. Centers for Disease Control and Prevention (CDC). （原始内容存档于2013-05-17）.
Antiviral Drug Resistance among Influenza Viruses. U.S. Centers for Disease Control and Prevention (CDC). 2019-04-17 [2020-01-29]. （原始内容存档于2014-02-13）.

clincalc.com (Global: 3,912^th place; Chinese: 5,917^th place)

The Top 300 of 2023. ClinCalc. [2025-08-17]. （原始内容存档于2025-08-17）.
Oseltamivir Drug Usage Statistics, United States, 2014 - 2023. ClinCalc. [2025-08-17].

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. The Journal of Antimicrobial Chemotherapy. April 2010, 65 (Suppl 2): ii5–ii10. PMC 2835511 . PMID 20215135. doi:10.1093/jac/dkq015.
Butler D. Tamiflu report comes under fire. Nature. April 2014, 508 (7497): 439–40. Bibcode:2014Natur.508..439B. PMID 24759392. doi:10.1038/508439a .
Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. Jefferson T , 编. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLOS ONE. 2013, 8 (4): e60348. Bibcode:2013PLoSO...860348M. PMC 3614893 . PMID 23565231. doi:10.1371/journal.pone.0060348 .
Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Family Practice. April 2013, 30 (2): 125–33. PMID 22997224. doi:10.1093/fampra/cms059 .
Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLOS ONE. 2014-12-09, 9 (12): e113633. Bibcode:2014PLoSO...9k3633O. PMC 4260958 . PMID 25490762. doi:10.1371/journal.pone.0113633.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Harnden A , 编. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). The Cochrane Database of Systematic Reviews. April 2012, 4 (4): CD002744. PMC 6599832 . PMID 22513907. doi:10.1002/14651858.CD002744.pub4.
Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. April 2014, 348: g2545. PMC 3981975 . PMID 24811411. doi:10.1136/bmj.g2545.
Agrawal R, Rewatkar PV, Kokil GR, Verma A, Kalra A. Oseltamivir: a first line defense against swine flu. Medicinal Chemistry. July 2010, 6 (4): 247–51. PMID 20843284. doi:10.2174/1573406411006040247.
Ebell MH. WHO downgrades status of oseltamivir. BMJ. July 2017, 358: j3266 [2020-08-31]. PMID 28701339. S2CID 206916214. doi:10.1136/bmj.j3266. （原始内容存档于2023-04-29）.
Kmietowicz Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ. June 2017, 357: j2841. PMID 28607038. S2CID 42931361. doi:10.1136/bmj.j2841.
Committee On Infectious Diseases. Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics. November 2014, 134 (5): e1503–19. PMID 25246619. doi:10.1542/peds.2014-2413 .
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. The Cochrane Database of Systematic Reviews. April 2014, 4 (4): CD008965. PMC 6464969 . PMID 24718923. doi:10.1002/14651858.CD008965.pub4.
Musher DM, Thorner AR. Community-acquired pneumonia. New England Journal of Medicine. October 2014, 371 (17): 1619–28. PMID 25337751. doi:10.1056/NEJMra1312885.
Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infectious Diseases. 2015, 47 (11): 808–819. PMID 26173991. S2CID 207746253. doi:10.3109/23744235.2015.1067369.
Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technology Assessment. May 2016, 20 (42): 1–242. PMC 4904189 . PMID 27246259. doi:10.3310/hta20420.
Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases. May 2018, 66 (10): 1492–1500. PMID 29186364. doi:10.1093/cid/cix1040 .
Holzinger F, Beck S, Dini L, Stöter C, Heintze C. The diagnosis and treatment of acute cough in adults. Deutsches Ärzteblatt International. May 2014, 111 (20): 356–63. PMC 4047603 . PMID 24882627. doi:10.3238/arztebl.2014.0356.
Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clinical Infectious Diseases. August 2011, 53 (3): 277–9. PMC 3137795 . PMID 21677258. doi:10.1093/cid/cir400.
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. May 2015, 385 (9979): 1729–37. PMID 25640810. S2CID 30589393. doi:10.1016/S0140-6736(14)62449-1.
Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. The Lancet. Infectious Diseases. September 2009, 9 (9): 537–45. PMID 19665930. doi:10.1016/S1473-3099(09)70199-9.
Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, Nicholson KG. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. The Journal of Infection. January 2011, 62 (1): 14–25. PMID 20950645. doi:10.1016/j.jinf.2010.10.003 .
Antipov EA, Pokryshevskaya EB. The effects of adverse drug reactions on patients' satisfaction: evidence from publicly available data on tamiflu (oseltamivir). International Journal of Medical Informatics. 2019, 125: 30–36. PMID 30914178. doi:10.1016/j.ijmedinf.2019.02.005.
Cohen D. Oseltamivir: another case of regulatory failure?. BMJ. 2014-04-09, 348 (apr09 8): g2591. S2CID 72592926. doi:10.1136/bmj.g2591.
Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infectious Diseases. May 2011, 11 (1). PMC 3123567 . PMID 21592407. doi:10.1186/1471-2334-11-134 . 已忽略未知参数|article-number= (帮助)
Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. The Journal of Antimicrobial Chemotherapy. February 2005, 55 (Suppl 1): i5–i21. PMID 15709056. doi:10.1093/jac/dki018 .
Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. April 2007, 297 (13): 1435–42. PMID 17405969. doi:10.1001/jama.297.13.1435 .
McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses. January 2013, 7 (Suppl 1): 25–36. PMC 4942987 . PMID 23279894. doi:10.1111/irv.12047.
Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet. June 2013, 381 (9885): 2230–2. PMID 23809549. S2CID 39375028. doi:10.1016/S0140-6736(13)61209-X.
Farina V, Brown JD. Tamiflu: the supply problem. Angewandte Chemie. November 2006, 45 (44): 7330–4. Bibcode:2006ACIE...45.7330F. PMID 17051628. doi:10.1002/anie.200602623.
Rawat G, Tripathi P, Saxena RK. Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends. Applied Microbiology and Biotechnology. May 2013, 97 (10): 4277–87. PMID 23553030. S2CID 17660413. doi:10.1007/s00253-013-4840-y .
Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine. July 2003, 163 (14): 1667–72. PMID 12885681. doi:10.1001/archinte.163.14.1667 .
Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Jefferson T , 编. Neuraminidase inhibitors for preventing and treating influenza in healthy adults (PDF). The Cochrane Database of Systematic Reviews. July 2006, (3): CD001265 [2019-09-24]. PMC 2790574 . PMID 16855962. doi:10.1002/14651858.CD001265.pub2. （原始内容存档 (PDF)于2021-08-28）. （已撤稿，见doi:10.1002/14651858.cd001265.pub3)
Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ. April 2014, 348 (apr10 14): g2263. PMID 24721793. S2CID 13490764. doi:10.1136/bmj.g2263.
Cohen D. Roche offers researchers access to all Tamiflu trials. BMJ. April 2013, 346 (apr04 3): f2157. PMID 23558407. S2CID 5469580. doi:10.1136/bmj.f2157.
Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza Activity Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. J. Am. Chem. Soc.; (Article); 1997; 119(4); 681-690. doi:10.1021/ja963036t
Practical Total Synthesis of the Anti-Influenza Drug GS-4104 John C. Rohloff, Kenneth M. Kent, Michael J. Postich, Mark W. Becker, Harlan H. Chapman, Daphne E. Kelly, Willard Lew, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, Lisa M. Schultze, Richard H. Yu, and Lijun Zhang J. Org. Chem.; 1998; 63(13) pp 4545 - 4550; (Note) doi:10.1021/jo980330q.
Savigny MR, Macintire DK. Use of oseltamivir in the treatment of canine parvoviral enteritis. Journal of Veterinary Emergency and Critical Care. February 2010, 20 (1): 132–42. PMID 20230441. doi:10.1111/j.1476-4431.2009.00404.x.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. March 2020, 323 (11): 1061–1069. PMC 7042881 . PMID 32031570. doi:10.1001/jama.2020.1585.

drugs.com (Global: 399^th place; Chinese: 208^th place)

Oseltamivir (Tamiflu) Use During Pregnancy. Drugs.com. [2017-01-16]. （原始内容存档于2017-09-09）.
Oseltamivir Phosphate Monograph for Professionals. The American Society of Health-System Pharmacists. [2017-01-08]. （原始内容存档于2016-05-13）.

europa.eu (Global: 68^th place; Chinese: 209^th place)

ecdc.europa.eu

European Centre for Disease Prevention and Control. New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published. 2014-06-02 [2020-07-20]. （原始内容存档于2014-11-02）.
Main surveillance developments in week 51/2011 (19–25 December 2011) (PDF). European Centre for Disease Prevention and Control (ECDC). January 2012. （原始内容存档 (PDF)于2012-06-10）.

fda.gov (Global: 447^th place; Chinese: 581^st place)

accessdata.fda.gov

Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-01-09]. （原始内容存档于2017-11-30）.
Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087. 2001-03-30. （原始内容存档于2014-04-16）.
FDA Prescribing Information (PDF). US FDA. [2025-02-13]. （原始内容 (PDF)存档于2017-01-18）.
Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087. U.S. Food and Drug Administration (FDA). 1999-12-24 [2020-01-09]. （原始内容存档于2020-01-19）.

fda.gov

The FDA approves first generic version of widely used influenza drug, Tamiflu. U.S. Food and Drug Administration (FDA). 2016-08-04 [2016-08-06]. （原始内容存档于2016-08-08）.
Pediatric safety update for Tamiflu (PDF). U.S. Food and Drug Administration (FDA). （原始内容 (PDF)存档于2007-09-27）.

gov.uk (Global: 432^nd place; Chinese: 770^th place)

Public Health England. The use of antivirals for the treatment and prophylaxis of influenza: PHE summary of current guidance for healthcare professionals (PDF). November 2014. （原始内容存档 (PDF)于8 December 2014）.

guildlink.com.au (Global: low place; Chinese: low place)

Roche Products Pty Limited. Tamiflu (oseltamivir phosphate). Australian Product Information. [2023-01-09]. （原始内容存档于24 April 2023）.

handle.net (Global: 102^nd place; Chinese: 492^nd place)

hdl.handle.net

World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. 2017. ISBN 9789241210157. hdl:10665/259481 . WHO technical report series;1006. License: CC BY-NC-SA 3.0 IGO.
World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu (Global: 18^th place; Chinese: 57^th place)

ui.adsabs.harvard.edu

Butler D. Tamiflu report comes under fire. Nature. April 2014, 508 (7497): 439–40. Bibcode:2014Natur.508..439B. PMID 24759392. doi:10.1038/508439a .
Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. Jefferson T , 编. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLOS ONE. 2013, 8 (4): e60348. Bibcode:2013PLoSO...860348M. PMC 3614893 . PMID 23565231. doi:10.1371/journal.pone.0060348 .
Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLOS ONE. 2014-12-09, 9 (12): e113633. Bibcode:2014PLoSO...9k3633O. PMC 4260958 . PMID 25490762. doi:10.1371/journal.pone.0113633.
Farina V, Brown JD. Tamiflu: the supply problem. Angewandte Chemie. November 2006, 45 (44): 7330–4. Bibcode:2006ACIE...45.7330F. PMID 17051628. doi:10.1002/anie.200602623.

idsociety.org (Global: low place; Chinese: 6,969^th place)

IDSA Continues to Recommend Antivirals for Influenza. [2014-04-24]. （原始内容存档于2014-04-24）.

indiatimes.com (Global: 17^th place; Chinese: 397^th place)

timesofindia.indiatimes.com

Cipla's anti-flu drug gets nod. The Times of India. 14 May 2009 [2009-07-29]. （原始内容存档于2012-10-23）.

medscape.com (Global: 719^th place; Chinese: 889^th place)

Waknine Y. Tamiflu May Be Linked to Risk for Self-Injury and Delirium. Medscape. 14 November 2006 [2008-05-17]. （原始内容存档于2011-11-25）.

nc.gov (Global: low place; Chinese: low place)

immunize.nc.gov

CDC Influenza Division Key Points, March 28, 2014 (PDF). U.S. Centers for Disease Control and Prevention (CDC). 2014-03-28 [2014-04-15]. （原始内容 (PDF)存档于2014-04-02）.

nice.org.uk (Global: 3,258^th place; Chinese: 2,433^rd place)

Amantadine, oseltamivir and zanamivir for the treatment of influenza. National Institute for Health and Care Excellence (NICE). 2009-02-25 [2017-01-16]. （原始内容存档于2017-01-18）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. The Journal of Antimicrobial Chemotherapy. April 2010, 65 (Suppl 2): ii5–ii10. PMC 2835511 . PMID 20215135. doi:10.1093/jac/dkq015.
Butler D. Tamiflu report comes under fire. Nature. April 2014, 508 (7497): 439–40. Bibcode:2014Natur.508..439B. PMID 24759392. doi:10.1038/508439a .
Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. Jefferson T , 编. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLOS ONE. 2013, 8 (4): e60348. Bibcode:2013PLoSO...860348M. PMC 3614893 . PMID 23565231. doi:10.1371/journal.pone.0060348 .
Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Family Practice. April 2013, 30 (2): 125–33. PMID 22997224. doi:10.1093/fampra/cms059 .
Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLOS ONE. 2014-12-09, 9 (12): e113633. Bibcode:2014PLoSO...9k3633O. PMC 4260958 . PMID 25490762. doi:10.1371/journal.pone.0113633.
Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Harnden A , 编. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). The Cochrane Database of Systematic Reviews. April 2012, 4 (4): CD002744. PMC 6599832 . PMID 22513907. doi:10.1002/14651858.CD002744.pub4.
Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. April 2014, 348: g2545. PMC 3981975 . PMID 24811411. doi:10.1136/bmj.g2545.
Agrawal R, Rewatkar PV, Kokil GR, Verma A, Kalra A. Oseltamivir: a first line defense against swine flu. Medicinal Chemistry. July 2010, 6 (4): 247–51. PMID 20843284. doi:10.2174/1573406411006040247.
Ebell MH. WHO downgrades status of oseltamivir. BMJ. July 2017, 358: j3266 [2020-08-31]. PMID 28701339. S2CID 206916214. doi:10.1136/bmj.j3266. （原始内容存档于2023-04-29）.
Kmietowicz Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ. June 2017, 357: j2841. PMID 28607038. S2CID 42931361. doi:10.1136/bmj.j2841.
Committee On Infectious Diseases. Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics. November 2014, 134 (5): e1503–19. PMID 25246619. doi:10.1542/peds.2014-2413 .
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. The Cochrane Database of Systematic Reviews. April 2014, 4 (4): CD008965. PMC 6464969 . PMID 24718923. doi:10.1002/14651858.CD008965.pub4.
Musher DM, Thorner AR. Community-acquired pneumonia. New England Journal of Medicine. October 2014, 371 (17): 1619–28. PMID 25337751. doi:10.1056/NEJMra1312885.
Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infectious Diseases. 2015, 47 (11): 808–819. PMID 26173991. S2CID 207746253. doi:10.3109/23744235.2015.1067369.
Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technology Assessment. May 2016, 20 (42): 1–242. PMC 4904189 . PMID 27246259. doi:10.3310/hta20420.
Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases. May 2018, 66 (10): 1492–1500. PMID 29186364. doi:10.1093/cid/cix1040 .
Holzinger F, Beck S, Dini L, Stöter C, Heintze C. The diagnosis and treatment of acute cough in adults. Deutsches Ärzteblatt International. May 2014, 111 (20): 356–63. PMC 4047603 . PMID 24882627. doi:10.3238/arztebl.2014.0356.
Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clinical Infectious Diseases. August 2011, 53 (3): 277–9. PMC 3137795 . PMID 21677258. doi:10.1093/cid/cir400.
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. May 2015, 385 (9979): 1729–37. PMID 25640810. S2CID 30589393. doi:10.1016/S0140-6736(14)62449-1.
Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. The Lancet. Infectious Diseases. September 2009, 9 (9): 537–45. PMID 19665930. doi:10.1016/S1473-3099(09)70199-9.
Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, Nicholson KG. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. The Journal of Infection. January 2011, 62 (1): 14–25. PMID 20950645. doi:10.1016/j.jinf.2010.10.003 .
Antipov EA, Pokryshevskaya EB. The effects of adverse drug reactions on patients' satisfaction: evidence from publicly available data on tamiflu (oseltamivir). International Journal of Medical Informatics. 2019, 125: 30–36. PMID 30914178. doi:10.1016/j.ijmedinf.2019.02.005.
Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infectious Diseases. May 2011, 11 (1). PMC 3123567 . PMID 21592407. doi:10.1186/1471-2334-11-134 . 已忽略未知参数|article-number= (帮助)
Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. The Journal of Antimicrobial Chemotherapy. February 2005, 55 (Suppl 1): i5–i21. PMID 15709056. doi:10.1093/jac/dki018 .
Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. April 2007, 297 (13): 1435–42. PMID 17405969. doi:10.1001/jama.297.13.1435 .
McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses. January 2013, 7 (Suppl 1): 25–36. PMC 4942987 . PMID 23279894. doi:10.1111/irv.12047.
Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet. June 2013, 381 (9885): 2230–2. PMID 23809549. S2CID 39375028. doi:10.1016/S0140-6736(13)61209-X.
Farina V, Brown JD. Tamiflu: the supply problem. Angewandte Chemie. November 2006, 45 (44): 7330–4. Bibcode:2006ACIE...45.7330F. PMID 17051628. doi:10.1002/anie.200602623.
Rawat G, Tripathi P, Saxena RK. Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends. Applied Microbiology and Biotechnology. May 2013, 97 (10): 4277–87. PMID 23553030. S2CID 17660413. doi:10.1007/s00253-013-4840-y .
Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives of Internal Medicine. July 2003, 163 (14): 1667–72. PMID 12885681. doi:10.1001/archinte.163.14.1667 .
Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Jefferson T , 编. Neuraminidase inhibitors for preventing and treating influenza in healthy adults (PDF). The Cochrane Database of Systematic Reviews. July 2006, (3): CD001265 [2019-09-24]. PMC 2790574 . PMID 16855962. doi:10.1002/14651858.CD001265.pub2. （原始内容存档 (PDF)于2021-08-28）. （已撤稿，见doi:10.1002/14651858.cd001265.pub3)
Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ. April 2014, 348 (apr10 14): g2263. PMID 24721793. S2CID 13490764. doi:10.1136/bmj.g2263.
Cohen D. Roche offers researchers access to all Tamiflu trials. BMJ. April 2013, 346 (apr04 3): f2157. PMID 23558407. S2CID 5469580. doi:10.1136/bmj.f2157.
Savigny MR, Macintire DK. Use of oseltamivir in the treatment of canine parvoviral enteritis. Journal of Veterinary Emergency and Critical Care. February 2010, 20 (1): 132–42. PMID 20230441. doi:10.1111/j.1476-4431.2009.00404.x.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. March 2020, 323 (11): 1061–1069. PMC 7042881 . PMID 32031570. doi:10.1001/jama.2020.1585.

dailymed.nlm.nih.gov

Tamiflu- oseltamivir phosphate capsule Tamiflu- oseltamivir phosphate powder, for suspension. DailyMed. 2019 -11-15 [2020-01-30]. （原始内容存档于2020-10-28）. 请检查|date=中的日期值 (帮助)

reuters.com (Global: 49^th place; Chinese: 81^st place)

Researchers, regulators and Roche row over stockpiled drug Tamiflu. Reuters. 2014-04-09. （原始内容存档于2015-09-24）.

rocheusa.com (Global: low place; Chinese: low place)

Roche – Doing now what patients need next (PDF). （原始内容 (PDF)存档于2005-11-03）.

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

api.semanticscholar.org

Ebell MH. WHO downgrades status of oseltamivir. BMJ. July 2017, 358: j3266 [2020-08-31]. PMID 28701339. S2CID 206916214. doi:10.1136/bmj.j3266. （原始内容存档于2023-04-29）.
Kmietowicz Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ. June 2017, 357: j2841. PMID 28607038. S2CID 42931361. doi:10.1136/bmj.j2841.
Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infectious Diseases. 2015, 47 (11): 808–819. PMID 26173991. S2CID 207746253. doi:10.3109/23744235.2015.1067369.
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. May 2015, 385 (9979): 1729–37. PMID 25640810. S2CID 30589393. doi:10.1016/S0140-6736(14)62449-1.
Cohen D. Oseltamivir: another case of regulatory failure?. BMJ. 2014-04-09, 348 (apr09 8): g2591. S2CID 72592926. doi:10.1136/bmj.g2591.
Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet. June 2013, 381 (9885): 2230–2. PMID 23809549. S2CID 39375028. doi:10.1016/S0140-6736(13)61209-X.
Rawat G, Tripathi P, Saxena RK. Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends. Applied Microbiology and Biotechnology. May 2013, 97 (10): 4277–87. PMID 23553030. S2CID 17660413. doi:10.1007/s00253-013-4840-y .
Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ. April 2014, 348 (apr10 14): g2263. PMID 24721793. S2CID 13490764. doi:10.1136/bmj.g2263.
Cohen D. Roche offers researchers access to all Tamiflu trials. BMJ. April 2013, 346 (apr04 3): f2157. PMID 23558407. S2CID 5469580. doi:10.1136/bmj.f2157.

sina.com.cn (Global: 144^th place; Chinese: 3^rd place)

news.sina.com.cn

肺炎事件续：“达菲”涉嫌造谣广东公安厅调查. 南方都市报. 2003年2月15日 [2013-12-06]. （原始内容存档于2020-12-06）.

tga.gov.au (Global: 3,984^th place; Chinese: 1,603^rd place)

ALEMBIC OSELTAMIVIR, ALEMVIR, ALEMZY, OSELEMBIC, OSELTAMIVIR AGH, OSELTAMIVIR AGHL, OSELTAMIVIR APPL, TAMIRAC (Alembic Pharmaceuticals Australia Pty Ltd). Therapeutic Goods Administration (TGA). 2022-12-05 [2023-04-29]. （原始内容存档于2023-03-18）.
Prescribing medicines in pregnancy database. Australian Government. 2014-03-03 [2014-04-22]. （原始内容存档于2014-04-08）.

theatlantic.com (Global: 228^th place; Chinese: 597^th place)

Brownlee S. Tamiflu: Myth and Misconception. The Atlantic. 2013-02-19 [2014-12-07]. （原始内容存档于2014-12-29）.
Brownlee S, Lenzer J. Does the Vaccine Matter?. The Atlantic. November 2009. （原始内容存档于2010-01-04）.

umn.edu (Global: 1,266^th place; Chinese: 1,781^st place)

cidrap.umn.edu

Heiberg M. Oseltamivir-resistant H5N1 virus isolated from Vietnamese girl. University of Minnesota. 14 October 2005 [2014-12-07]. （原始内容存档于2014-12-14）.

uq.edu.au (Global: 3,558^th place; Chinese: 2,972^nd place)

espace.library.uq.edu.au

Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Jefferson T , 编. Neuraminidase inhibitors for preventing and treating influenza in healthy adults (PDF). The Cochrane Database of Systematic Reviews. July 2006, (3): CD001265 [2019-09-24]. PMC 2790574 . PMID 16855962. doi:10.1002/14651858.CD001265.pub2. （原始内容存档 (PDF)于2021-08-28）. （已撤稿，见doi:10.1002/14651858.cd001265.pub3)

vin.com (Global: low place; Chinese: low place)

Macintire, Douglass K. Treatment of Parvoviral Enteritis. Proceedings of the Western Veterinary Conference. 2006 [2007-06-09]. （原始内容存档于2021-08-28）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Oseltamivir (Tamiflu) Use During Pregnancy. Drugs.com. [2017-01-16]. （原始内容存档于2017-09-09）.
Roche Products Pty Limited. Tamiflu (oseltamivir phosphate). Australian Product Information. [2023-01-09]. （原始内容存档于24 April 2023）.
ALEMBIC OSELTAMIVIR, ALEMVIR, ALEMZY, OSELEMBIC, OSELTAMIVIR AGH, OSELTAMIVIR AGHL, OSELTAMIVIR APPL, TAMIRAC (Alembic Pharmaceuticals Australia Pty Ltd). Therapeutic Goods Administration (TGA). 2022-12-05 [2023-04-29]. （原始内容存档于2023-03-18）.
Oseltamivir Phosphate Monograph for Professionals. The American Society of Health-System Pharmacists. [2017-01-08]. （原始内容存档于2016-05-13）.
CDC Recommendations for Influenza Antiviral Medications Remain Unchanged. U.S. Centers for Disease Control and Prevention (CDC). 2014-04-10 [2017-01-16]. （原始内容存档于2017-01-18）.
European Centre for Disease Prevention and Control. New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published. 2014-06-02 [2020-07-20]. （原始内容存档于2014-11-02）.
Amantadine, oseltamivir and zanamivir for the treatment of influenza. National Institute for Health and Care Excellence (NICE). 2009-02-25 [2017-01-16]. （原始内容存档于2017-01-18）.
IDSA Continues to Recommend Antivirals for Influenza. [2014-04-24]. （原始内容存档于2014-04-24）.
Brownlee S. Tamiflu: Myth and Misconception. The Atlantic. 2013-02-19 [2014-12-07]. （原始内容存档于2014-12-29）.
Ebell MH. WHO downgrades status of oseltamivir. BMJ. July 2017, 358: j3266 [2020-08-31]. PMID 28701339. S2CID 206916214. doi:10.1136/bmj.j3266. （原始内容存档于2023-04-29）.
The FDA approves first generic version of widely used influenza drug, Tamiflu. U.S. Food and Drug Administration (FDA). 2016-08-04 [2016-08-06]. （原始内容存档于2016-08-08）.
Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-01-09]. （原始内容存档于2017-11-30）.
The Top 300 of 2023. ClinCalc. [2025-08-17]. （原始内容存档于2025-08-17）.
Tamiflu- oseltamivir phosphate capsule Tamiflu- oseltamivir phosphate powder, for suspension. DailyMed. 2019 -11-15 [2020-01-30]. （原始内容存档于2020-10-28）. 请检查|date=中的日期值 (帮助)
Influenza Antiviral Medications: Summary for Clinicians. U.S. Centers for Disease Control and Prevention (CDC). 2014-12-03 [2014-12-09]. （原始内容存档于2014-12-13）.
Public Health England. The use of antivirals for the treatment and prophylaxis of influenza: PHE summary of current guidance for healthcare professionals (PDF). November 2014. （原始内容存档 (PDF)于8 December 2014）.
Researchers, regulators and Roche row over stockpiled drug Tamiflu. Reuters. 2014-04-09. （原始内容存档于2015-09-24）.
Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087. 2001-03-30. （原始内容存档于2014-04-16）.
FDA Prescribing Information (PDF). US FDA. [2025-02-13]. （原始内容 (PDF)存档于2017-01-18）.
Roche – Doing now what patients need next (PDF). （原始内容 (PDF)存档于2005-11-03）.
Pediatric safety update for Tamiflu (PDF). U.S. Food and Drug Administration (FDA). （原始内容 (PDF)存档于2007-09-27）.
Waknine Y. Tamiflu May Be Linked to Risk for Self-Injury and Delirium. Medscape. 14 November 2006 [2008-05-17]. （原始内容存档于2011-11-25）.
Prescribing medicines in pregnancy database. Australian Government. 2014-03-03 [2014-04-22]. （原始内容存档于2014-04-08）.
Update on oseltamivir resistance to influenza H1N1 (2009) viruses (PDF). World Health Organization (WHO). 15 December 2010 [2010-12-30]. （原始内容存档 (PDF)于2011-01-27）.
2010-2011 Influenza Season Summary. U.S. Centers for Disease Control and Prevention (CDC). （原始内容存档于2012-01-25）.
2011-2012 Influenza Season Week 51 ending December 24, 2011. U.S. Centers for Disease Control and Prevention (CDC). （原始内容存档于2013-05-17）.
Main surveillance developments in week 51/2011 (19–25 December 2011) (PDF). European Centre for Disease Prevention and Control (ECDC). January 2012. （原始内容存档 (PDF)于2012-06-10）.
CDC Influenza Division Key Points, March 28, 2014 (PDF). U.S. Centers for Disease Control and Prevention (CDC). 2014-03-28 [2014-04-15]. （原始内容 (PDF)存档于2014-04-02）.
Antiviral Drug Resistance among Influenza Viruses. U.S. Centers for Disease Control and Prevention (CDC). 2019-04-17 [2020-01-29]. （原始内容存档于2014-02-13）.
Avian Flu Drugs: Patent Questions. WIPO. April 2006. （原始内容存档于8 December 2009）.
Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087. U.S. Food and Drug Administration (FDA). 1999-12-24 [2020-01-09]. （原始内容存档于2020-01-19）.
Heiberg M. Oseltamivir-resistant H5N1 virus isolated from Vietnamese girl. University of Minnesota. 14 October 2005 [2014-12-07]. （原始内容存档于2014-12-14）.
Brownlee S, Lenzer J. Does the Vaccine Matter?. The Atlantic. November 2009. （原始内容存档于2010-01-04）.
Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Jefferson T , 编. Neuraminidase inhibitors for preventing and treating influenza in healthy adults (PDF). The Cochrane Database of Systematic Reviews. July 2006, (3): CD001265 [2019-09-24]. PMC 2790574 . PMID 16855962. doi:10.1002/14651858.CD001265.pub2. （原始内容存档 (PDF)于2021-08-28）. （已撤稿，见doi:10.1002/14651858.cd001265.pub3)
Cipla's anti-flu drug gets nod. The Times of India. 14 May 2009 [2009-07-29]. （原始内容存档于2012-10-23）.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010 (PDF). WHO. （原始内容存档 (PDF)于2013-10-27）.
Tamiflu campaign. BMJ. [2020-01-21]. （原始内容存档于2020-01-21）.
肺炎事件续：“达菲”涉嫌造谣广东公安厅调查. 南方都市报. 2003年2月15日 [2013-12-06]. （原始内容存档于2020-12-06）.
Macintire, Douglass K. Treatment of Parvoviral Enteritis. Proceedings of the Western Veterinary Conference. 2006 [2007-06-09]. （原始内容存档于2021-08-28）.

who.int (Global: 195^th place; Chinese: 179^th place)

Update on oseltamivir resistance to influenza H1N1 (2009) viruses (PDF). World Health Organization (WHO). 15 December 2010 [2010-12-30]. （原始内容存档 (PDF)于2011-01-27）.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010 (PDF). WHO. （原始内容存档 (PDF)于2013-10-27）.

wipo.int (Global: 1,462^nd place; Chinese: 2,636^th place)

Avian Flu Drugs: Patent Questions. WIPO. April 2006. （原始内容存档于8 December 2009）.

奥司他韦 (Chinese Wikipedia)

archive.org (Global: 6th place; Chinese: 4th place)

bmj.com (Global: 1,226th place; Chinese: 890th place)

cdc.gov (Global: 218th place; Chinese: 198th place)

clincalc.com (Global: 3,912th place; Chinese: 5,917th place)

doi.org (Global: 2nd place; Chinese: 23rd place)

drugs.com (Global: 399th place; Chinese: 208th place)

europa.eu (Global: 68th place; Chinese: 209th place)

ecdc.europa.eu

fda.gov (Global: 447th place; Chinese: 581st place)

accessdata.fda.gov

fda.gov

gov.uk (Global: 432nd place; Chinese: 770th place)

guildlink.com.au (Global: low place; Chinese: low place)

handle.net (Global: 102nd place; Chinese: 492nd place)

hdl.handle.net

harvard.edu (Global: 18th place; Chinese: 57th place)

ui.adsabs.harvard.edu

idsociety.org (Global: low place; Chinese: 6,969th place)

indiatimes.com (Global: 17th place; Chinese: 397th place)

timesofindia.indiatimes.com

medscape.com (Global: 719th place; Chinese: 889th place)

nc.gov (Global: low place; Chinese: low place)

immunize.nc.gov

nice.org.uk (Global: 3,258th place; Chinese: 2,433rd place)

nih.gov (Global: 4th place; Chinese: 5th place)

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

reuters.com (Global: 49th place; Chinese: 81st place)

rocheusa.com (Global: low place; Chinese: low place)

semanticscholar.org (Global: 11th place; Chinese: 332nd place)

api.semanticscholar.org

sina.com.cn (Global: 144th place; Chinese: 3rd place)

news.sina.com.cn

tga.gov.au (Global: 3,984th place; Chinese: 1,603rd place)

theatlantic.com (Global: 228th place; Chinese: 597th place)

umn.edu (Global: 1,266th place; Chinese: 1,781st place)

cidrap.umn.edu

uq.edu.au (Global: 3,558th place; Chinese: 2,972nd place)

espace.library.uq.edu.au

vin.com (Global: low place; Chinese: low place)

web.archive.org (Global: 1st place; Chinese: 1st place)

who.int (Global: 195th place; Chinese: 179th place)

wipo.int (Global: 1,462nd place; Chinese: 2,636th place)

archive.org (Global: 6^th place; Chinese: 4^th place)

bmj.com (Global: 1,226^th place; Chinese: 890^th place)

cdc.gov (Global: 218^th place; Chinese: 198^th place)

clincalc.com (Global: 3,912^th place; Chinese: 5,917^th place)

doi.org (Global: 2^nd place; Chinese: 23^rd place)

drugs.com (Global: 399^th place; Chinese: 208^th place)

europa.eu (Global: 68^th place; Chinese: 209^th place)

fda.gov (Global: 447^th place; Chinese: 581^st place)

gov.uk (Global: 432^nd place; Chinese: 770^th place)

handle.net (Global: 102^nd place; Chinese: 492^nd place)

harvard.edu (Global: 18^th place; Chinese: 57^th place)

idsociety.org (Global: low place; Chinese: 6,969^th place)

indiatimes.com (Global: 17^th place; Chinese: 397^th place)

medscape.com (Global: 719^th place; Chinese: 889^th place)

nice.org.uk (Global: 3,258^th place; Chinese: 2,433^rd place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

reuters.com (Global: 49^th place; Chinese: 81^st place)

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

sina.com.cn (Global: 144^th place; Chinese: 3^rd place)

tga.gov.au (Global: 3,984^th place; Chinese: 1,603^rd place)

theatlantic.com (Global: 228^th place; Chinese: 597^th place)

umn.edu (Global: 1,266^th place; Chinese: 1,781^st place)

uq.edu.au (Global: 3,558^th place; Chinese: 2,972^nd place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

who.int (Global: 195^th place; Chinese: 179^th place)

wipo.int (Global: 1,462^nd place; Chinese: 2,636^th place)